<DOC>
	<DOCNO>NCT00003243</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . White blood cell donor may able kill cancer cell patient hematologic cancer recur follow bone marrow transplantation . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus infusion donate white blood cell treat patient hematologic cancer recur bone marrow transplantation .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Infusion White Blood Cells Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose doxorubicin HCl liposome combine etoposide , cyclophosphamide , allogeneic donor lymphocyte infusion without interleukin-2 allogeneic bone marrow transplantation patient relapse persistent aggressive hematologic malignancy . OUTLINE : This partially randomize , dose-escalation study doxorubicin HCl liposome ( LipoDox ) . Patients enter 1 4 cohort . - Cohort 1 : Three six patient receive induction comprise etoposide IV 1 hour day 1-3 , cyclophosphamide IV 1-2 hour day 8 , allogeneic donor lymphocyte infusion day 10 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) IV daily begin day 10 continue blood count recover . - Cohort 2 : In absence dose-limiting toxicity ( DLT ) cohort 1 , 3-6 patient receive treatment cohort 1 LipoDox IV 2 hour day 1 . - Cohort 3 : In absence DLT cohort 2 , 3-6 patient randomize 1 2 treatment arm . - Arm I : Patients receive treatment cohort 1 plus high dose LipoDox IV 2 hour day 1 . - Arm II : Patients receive treatment cohort 1 interleukin-2 ( IL-2 ) SC day 10-12 . If DLT reach cohort 2 , 3-6 patient receive treatment arm II . - Cohort 4 : In absence DLT arm I II , patient receive treatment cohort 1 , LipoDox arm I , IL-2 arm II . Cohorts 3-6 patient receive escalate dos LipoDox maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 12-15 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse persistent acute leukemia , myelodysplasia , aggressive nonHodgkin 's lymphoma ( NHL ) , chronic myeloid leukemia transform phase ( accelerated phase blast crisis ) allogeneic bone marrow transplantation ( BMT ) Aggressive NHL define diffuse mixed , diffuse large cell , diffuse small noncleaved cell , lymphoblastic histology No active acute graft versus host disease ( GVHD ) extensive chronic GVHD PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : More 4 week Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No severe psychiatric illness mental deficiency PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 6 month since prior allogeneic BMT No concurrent interleukin2 No concurrent immunomodulatory medication ( e.g. , interferon ) Chemotherapy : Not specify Endocrine therapy : No concurrent steroids Radiotherapy : Not specify Surgery : Not specify Other : No concurrent immunosuppressive medication ( e.g. , cyclosporine ) GVHD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>